Home › Funds › RTW INVESTMENTS, LP › PTGX

RTW INVESTMENTS, LP position in PTGX

PROTAGONIST THERAPEUTICS INC · Health Care

RTW INVESTMENTS, LP reported holding 5,061,175 shares of PTGX (PROTAGONIST THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$713.1M, representing 7.20% of its reported portfolio and ranking #1 among its reported holdings. RTW INVESTMENTS, LP has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.06M sh
Reported value held$713.07M
Portfolio Weight7.20%
First reportedQ3 2023
Last changeHold
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RTW INVESTMENTS, LP's PTGX position evolved

RTW INVESTMENTS, LP first disclosed a stake in PTGX in Q3 2023 at 5,415,514 shares (US$90.3M). The position peaked in Q3 2026 at 5,061,175 shares, worth US$713.1M. Across 13 filings, RTW INVESTMENTS, LP increased the stake 4 time(s), trimmed it 3 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 5,061,175 shares valued at US$713.1M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 5.42M $90.33M New
Q4 2023 5.32M $121.88M Reduce
Q1 2024 5.32M $153.78M Hold
Q2 2024 5.29M $183.17M Reduce
Q3 2024 5.43M $244.18M Add
Q4 2024 5.50M $212.24M Add
Q1 2025 5.72M $276.59M Add
Q2 2025 5.76M $318.15M Add
Q3 2025 5.76M $382.39M Hold
Q4 2025 5.06M $441.86M Reduce
Q1 2026 5.06M $533.22M Hold
Q2 2026 5.06M $620.40M Hold
Q3 2026 5.06M $713.07M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PTGX and 13F data

PTGX (PROTAGONIST THERAPEUTICS INC) is a Health Care company. 48 other funds we track also report a position in PTGX — the largest reported positions include FARALLON CAPITAL MANAGEMENT, L.L.C. (US$907.0M), Farallon Capital Management (US$778.2M), JOHNSON & JOHNSON (US$345.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PTGX

All PTGX fund holders →

FAQ

How long has RTW INVESTMENTS, LP held PTGX?

RTW INVESTMENTS, LP has disclosed PTGX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RTW INVESTMENTS, LP's current position in PTGX?

As of Q3 2026, RTW INVESTMENTS, LP holds 5.06M shares of PTGX (PROTAGONIST THERAPEUTICS INC), valued at $713.07M, representing 7.20% of its reported portfolio and ranking #1.

Has RTW INVESTMENTS, LP been buying or selling PTGX?

In the latest 13F filing (Q3 2026), RTW INVESTMENTS, LP held unchanged its position in PTGX. The position peaked in Q3 2026 at 5.06M shares.

Which other funds hold PTGX?

Other major institutional holders of PTGX include FARALLON CAPITAL MANAGEMENT, L.L.C., Farallon Capital Management, JOHNSON & JOHNSON, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.